Lead Product(s) : Tralesinidase Alfa
Therapeutic Area : Genetic Disease
Study Phase : Phase II
Sponsor : Spruce Biosciences
Deal Size : Undisclosed
Deal Type : Acquisition
Spruce Unveils New Strategy and Acquires Drug for Sanfilippo Syndrome Type B
Details : Through the acquisition, Spruce will focus on the clinical development of AX 250 (tralesinidase alfa) enzyme replacement therapy (TA-ERT) for the treatment of Sanfilippo Syndrome Type B.
Product Name : AX 250
Product Type : Protein
Upfront Cash : Undisclosed
April 15, 2025
Lead Product(s) : Tralesinidase Alfa
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Sponsor : Spruce Biosciences
Deal Size : Undisclosed
Deal Type : Acquisition
Reset All
